Analysts think CAPR stock price could increase by 383%
Apr 06, 2025, 11:25 AM
13.38%
What does CAPR do
Capricor Therapeutics, based in Beverly Hills, develops biological therapies for serious medical conditions, focusing on CAP-1002 for Duchenne muscular dystrophy in Phase 3 trials. The company also utilizes exosome technology for various therapeutic applications.
9 analysts think CAPR stock price will increase by 383.04%. The current median analyst target is $43.86 compared to a current stock price of $9.08. The lowest analysts target is $25.25 and the highest analyst target is $80.85.
📡️ Health Care
Price Target
More Signals
Feature in Progress
This section is under development. Check back soon for updates!
